Drugs that contain Bupropion Hydrochloride; Naltrexone Hydrochloride
1. List of Contrave drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11278544 | NALPROPION | Compositions for affecting weight loss |
Apr, 2024
(1 year, 1 month from now) | |
| US7462626 | NALPROPION | Compositions for affecting weight loss |
Jul, 2024
(1 year, 4 months from now) | |
| US8815889 | NALPROPION | Compositions and methods for increasing insulin sensitivity |
Jul, 2024
(1 year, 4 months from now) | |
| US7375111 | NALPROPION | Compositions for affecting weight loss |
Mar, 2025
(2 years from now) | |
| US9107837 | NALPROPION | Sustained release formulation of naltrexone |
Jun, 2027
(4 years from now) | |
| US8318788 | NALPROPION | Layered pharmaceutical formulations |
Nov, 2027
(4 years from now) | |
| US8722085 | NALPROPION | Methods for administering weight loss medications |
Nov, 2027
(4 years from now) | |
| US9125868 | NALPROPION | Methods for administering weight loss medications |
Nov, 2027
(4 years from now) | |
| US10307376 | NALPROPION | Methods for administering weight loss medications |
Nov, 2027
(4 years from now) | |
| US8088786 | NALPROPION | Layered pharmaceutical formulations |
Feb, 2029
(5 years from now) | |
| US11324741 | NALPROPION | Methods for treating visceral fat conditions |
May, 2029
(6 years from now) | |
| US8916195 | NALPROPION | Sustained release formulation of naltrexone |
Feb, 2030
(6 years from now) | |
| US11033543 | NALPROPION | Methods of providing weight loss therapy in patients with major depression |
Jan, 2031
(7 years from now) | |
| US9248123 | NALPROPION | Methods of providing weight loss therapy in patients with major depression |
Jan, 2032
(8 years from now) | |
| US10403170 | NALPROPION | Methods of treating overweight and obesity |
Jun, 2033
(10 years from now) | |
| US11139056 | NALPROPION | Methods of treating overweight and obesity |
Jun, 2033
(10 years from now) | |
| US9633575 | NALPROPION | Methods of treating overweight and obesity |
Jun, 2033
(10 years from now) | |
| US10231964 | NALPROPION | Compositions and methods for weight loss in at risk patient populations |
Jul, 2034
(11 years from now) | |
| US10828294 | NALPROPION | Compositions and methods for weight loss in at risk patient populations |
Jul, 2034
(11 years from now) | |
| US10835527 | NALPROPION | Compositions and methods for reducing major adverse cardiovascular events |
Jul, 2034
(11 years from now) | |
Market Authorisation Date: 10 September, 2014
Treatment: For chronic weight management for treating overweight or obesity; For effect on blood glucose parameters in patients with insulin resistance; Use of naltrexone and bupropion in extended-release form for chronic weight management for treating overweight or obesity; Use of naltrexone and bupropion in a layered formulation for chronic weight management for affecting weight loss; Use of naltrexone and bupropion based on an escalating dose schedule; Use of naltrexone and bupropion for chronic weight management for treating overweight or obesity in patients with major depressive disorder
Dosage: TABLET, EXTENDED RELEASE;ORAL
CONTRAVE family patents
81
United States
22
Japan
20
Korea, Republic of
20
European Union
12
Taiwan, Province of China
11
Spain
11
Mexico
10
Australia
9
China
8
Canada
7
Argentina
7
Denmark
6
Portugal
6
Russia
6
Israel
6
Poland
5
Hungary
4
Hong Kong
4
Chile
3
Brazil
3
Lithuania
3
RS
2
Germany
2
Austria
2
Morocco
2
Peru
2
EA
2
Tunisia
2
Slovenia
2
Ecuador
1
Singapore
1
Uruguay
1
Guatemala
1
Croatia
1
Costa Rica
1
Colombia
1
New Zealand
1
India
1
Nicaragua
1
Cyprus
1
Luxembourg
1
Netherlands
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic